Post hoc analyses of GOG 9923: Does BRCA status affect toxicities?: An NRG oncology study.

ABSTRACT:

Objective

To evaluate how women with epithelial ovarian cancer (EOC), dichotomized by BRCA status, tolerate intravenous (IV) or intraperitoneal (IP) chemotherapy given with veliparib and bevacizumab (bev) on a GOG phase I study (GOG 9923, NCT00989651).

Methods

This is an unplanned, post hoc analysis of an IRB approved, multi-institutional, prospective study (GOG 9923). Clinical characteristics and toxicity data based on BRCA status were evaluated and descriptive statistics were used to summarize baseline patient characteristics and toxicities. The Kaplan Meier method was used to generate survival estimates.

Results

Four hundred twenty-four patients were evaluable. Patients were treated with IV carboplatin, paclitaxel, and bev every 21 days (regimen 1), weekly IV pacli

SUBMITTER: Gillen J 

PROVIDER: S-EPMC8084973 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature